Sibutramine on Cardiovascular Outcome

Scheen, André

doi:10.2337/dc11-s205

Cited by 50 publications

(45 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sibutramine is a combined norepinephrine and SRI [34]. Data suggests that several CV adverse events as hypertension, tachycardia, arrhythmias, and myocardial infarction (MI) were reported in sibutramine-treated pts [34]. Results of previously performed study advise that sertraline is a safe and effective treatment for recurrent depression in pts with recent MI or unstable angina and without other life-threatening medical condition [35].…”

Section: Cardiac and Circulatory Effectsmentioning

confidence: 98%

See 1 more Smart Citation

Cardiovascular side effects of psychopharmacologic therapy

Potočnjak

Degoricija

Baudoin

et al. 2016

International Journal of Cardiology

View full text Add to dashboard Cite

Section: Cardiac and Circulatory Effectsmentioning

confidence: 98%

“…Psychotherapy and SSRIs, particularly sertraline, have been proven to be safe [33]. Sibutramine is a combined norepinephrine and SRI [34]. Data suggests that several CV adverse events as hypertension, tachycardia, arrhythmias, and myocardial infarction (MI) were reported in sibutramine-treated pts [34].…”

Section: Cardiac and Circulatory Effectsmentioning

confidence: 99%

Cardiovascular side effects of psychopharmacologic therapy

Potočnjak

Degoricija

Baudoin

et al. 2016

International Journal of Cardiology

View full text Add to dashboard Cite

“…Most studies showed no or only minimal changes in SBP, but a modest increase in DBP [24,25,26,27]. In patients who experience a clinically significant and sustained increase in blood pressure, the drug should be discontinued [24,28]. …”

Section: Discussionmentioning

confidence: 99%

Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial

Дедов

Melnichenko²,

Troshina³

et al. 2018

Obes Facts

View full text Add to dashboard Cite

Objective: The aim of the study was to assess the effectiveness and safety of long-term sibutramine therapy in routine clinical practice. Methods: In total, 98,774 patients (82.3% women, 17.7% men) from 142 cities of the Russian Federation were enrolled in the PRIMAVERA program. The mean age of the patients was 39.39 ± 10.38 years, the mean body weight was 99.1 ± 14.28 kg, and the mean BMI was 35.7 ± 4.41 kg/m². The duration of the sibutramine therapy was determined by physicians: 59.3% of patients took the drug for 6 months, the treatment course of 37.7% of patients was 12 months, and 3% of patients had treatment for 3 months. Results: The BMI reduction correlated with the treatment duration: 3.4 ± 1.53 kg/m² after 3 months of therapy, 5.4 ± 2.22 kg/m² after 6 months, and 7.2 ± 3.07 kg/m² after 12 months. The body weight reduction after 3, 6 and 12 months of treatment was 9.5%, 15.1%, and 19.7%, respectively. The body weight loss associated with sibutramine treatment was accompanied by a slight decrease in blood pressure and did not lead to any significant increases of the heart rate. Conclusions: The results of the PRIMAVERA study confirmed the lack of increased risk of using sibutramine in routine clinical practice in patients without underlying cardiovascular disease and low rate of adverse events.

show abstract

“…Sibutramine exerts a peripheral sympathomimetic effect that induces an increase in blood pressure and cardiac frequency, increasing the risk for tachycardia and arrythmia (Padwal and Majumdar, 2007). Thus, use of sibutramine can lead to hypertension, tachycardia, arrhythmia and myocardial infarction (Scheen, 2011). These adverse effects were confirmed by the sibutramine cardiovascular outcome trial (SCOUT), which showed that the drug increases the risk of non-fatal myocardial infarction and stroke in patients with preexisting cardiovascular disease (CVD) submitted to long-term treatment with sibutramine (10-15 mg/day) (Scheen, 2011).…”

Section: Introductionmentioning

confidence: 99%

“…Thus, use of sibutramine can lead to hypertension, tachycardia, arrhythmia and myocardial infarction (Scheen, 2011). These adverse effects were confirmed by the sibutramine cardiovascular outcome trial (SCOUT), which showed that the drug increases the risk of non-fatal myocardial infarction and stroke in patients with preexisting cardiovascular disease (CVD) submitted to long-term treatment with sibutramine (10-15 mg/day) (Scheen, 2011). For these reasons, the European Medicines Agency (EMA) recommended suspending marketing authorizations for sibutramine in the European Union (Scheen, 2011).…”

Section: Introductionmentioning

confidence: 99%

Can Spirulina maxima reduce the mutagenic potential of sibutramine?

Araldi

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The worldwide obesity pandemic requires the use of antiobesity drugs. Sibutramine is an anti-obesity drug that has been used worldwide but is indiscriminately consumed in Brazil. Several studies have demonstrated that sibutramine promotes weight loss and weight maintenance, but several side effects have been associated with its systematic consumption. For this reason, sibutramine was withdrawn from the European and American markets, but still remains legal for use in Brazil. Studies have shown that a 5-10% reduction in body weight results in outstanding health benefits for obese patients. However, in order to promote significant weight loss, it is necessary to use sibutramine for at least 2 years. This long-term exposure has carcinogenic potential, as sibutramine causes DNA damage. Thus, this study evaluated the in vivo mutagenic potential of sibutramine alone (5, 7, 10, 15, and 20 mg/kg) and in association with Spirulina maxima (150 and 300 mg/kg), a cyanobacterium with antioxidant potential, using the polychromatic erythrocyte micronucleus test. Our results reinforced the mutagenic potential of sibutramine alone, which showed a time-dependent action. Combinatory treatments with S. maxima were not able to reduce the genotoxicity of sibutramine. These results were confirmed in vitro with the cytokinesis-blocked micronucleus test. In conclusion, our data showed that new alternative anti-obesity treatments are needed since the consumption of sibutramine can increase the risk of cancer in overweight patients.

show abstract

Sibutramine on Cardiovascular Outcome

Cited by 50 publications

References 48 publications

Cardiovascular side effects of psychopharmacologic therapy

Cardiovascular side effects of psychopharmacologic therapy

Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial

Can Spirulina maxima reduce the mutagenic potential of sibutramine?

Contact Info

Product

Resources

About